WOODCLIFF LAKE, N.J.—Eisai Inc., the U.S. pharmaceutical
subsidiary of Tokyo-based Eisai Co. Ltd., and FORMA Therapeutics have signed a
strategic drug discovery collaboration. Under the terms of the agreement, Eisai
will have non-exclusive access to FORMA's Diversity Oriented Synthesis (DOS)
chemistry-generated compound library and cell-based screening platforms to
support the discovery of novel compounds for Eisai's pipeline. In addition,
Eisai has an option for technology transfer of FORMA’s cell-based screening
platform. FORMA will receive upfront payments and committed funding of $20
million over three years and is eligible to receive additional milestones plus
royalties on future products that Eisai may commercialize as a result of this
collaboration. Further details were not disclosed.
Click
here to print
